Andrew Farnsworth

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

Jesús F. San Miguel, Saad Z. Usmani, María‐Victoria Mateos et al. · Haematologica · 2020 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments

Joo Ern Ang, J.A. Clarkson-Jones, Helen Swaisland et al. · European Journal of Cancer Supplements · 2010 · 12 citations

Medicine, Pharmacokinetics, Pharmacology +8

Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).

Ajai Chari, María‐Victoria Mateos, Niels W.C.J. van de Donk et al. · Journal of Clinical Oncology · 2018 · 11 citations

Medicine, Pharmacology, Pharmacotherapy +16